Infasurf

Infasurf

Manufacturer:

ONY Biotech

Distributor:

Transmedic
Concise Prescribing Info
Contents
Calfactant (calf pulmonary surfactant)
Indications/Uses
Prevention of respiratory distress syndrome (RDS) in premature infants at high risk for RDS. Treatment ("rescue") of premature infants who develop RDS. Decreases the incidence of RDS, mortality due to RDS, and air leaks associated with RDS. Prophylaxis therapy at birth for premature infants <29 wk of gestational age at significant risk for RDS & infants ≤72 hr of age with RDS (confirmed by clinical and radiologic findings) and requiring endotracheal intubation.
Dosage/Direction for Use
3 mL/kg body wt at birth administered intratracheally 12 hrly for a total of up to 3 doses.
Adverse Reactions
Cyanosis, airway obstruction, bradycardia, reflux of surfactant into endotracheal tube, manual ventilation requirement & reintubation.
ATC Classification
R07AA - Lung surfactants ; Used in the treatment of respiratory diseases.
Presentation/Packing
Form
Infasurf intratracheal susp 35 mg/mL
Packing/Price
3 mL x 1's;6 mL x 1's
/singapore/image/info/infasurf intratracheal susp 35 mg-ml/3 ml?id=ca90b6e9-1ef2-4017-9075-a32201054f63
/singapore/image/info/infasurf intratracheal susp 35 mg-ml/6 ml?id=5b5a60ff-945a-43ae-baa5-a32201054f63
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $139 a year.
Sign up for free
Already a member? Sign in